drugset / Trial / NCT03038711

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers

NCT03038711

Phase 1 Completed 213 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindScreening

Summary

The purpose of this study is to understand if multiple oral doses of BMS-986166 are safe and well tolerated in healthy patients.

Timeline

Start
2017-02-01
Primary completion
2017-08-10
Completion
2017-08-10

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986166 Small molecule 0.25 mg Oral
Subject BMS-986166 Small molecule 0.75 mg Oral
Subject BMS-986166 Small molecule 1.5 mg Oral

Indications